Canadian Respiratory Journal / 2019 / Article / Tab 1

Research Article

Prognostic Value of Concomitant Bronchiectasis in Newly Diagnosed Diffuse Panbronchiolitis Patients on a Maintenance Therapy with Macrolides

Table 1

Demographic, clinical, and laboratory findings of DPB subjects with and without bronchiectasis at baseline.

ParameterWhole group ()DPB with bronchiectasis ()DPB without bronchiectasis () value

Age (years)52.5 ± 16.853.0 ± 16.651.9 ± 17.30.597
Female91 (41.9)59 (45.7)32 (36.4)0.108
BMI (kg/m2)21.3±5.319.7±3.923.8±6.2<0.001
Smoking history52 (24.0)34 (26.4)18 (20.5)0.317
Disease duration (year)7.0 (5.0, 9.0)7.0 (5.0, 10.5)6.5 (5.0, 9.0)0.088
Disease history
 Chronic sinusitis197 (90.8)116 (89.9)81 (92.0)0.596
 Chronic bronchitis19 (8.8)14 (10.9)5 (5.7)0.186
 Emphysema11 (5.1)7 (5.4)4 (4.5)0.771
 Preexisting tuberculosis24 (11.1)17 (13.2)7 (8.0)0.228
 Hypertension42 (19.4)23 (17.8)19 (21.6)0.491
 Diabetes10 (4.6)6 (4.7)4 (4.5)0.971
 Cardiovascular diseases14 (6.5)9 (7.0)5 (5.7)0.703
 Rheumatic diseases10 (4.6)6 (4.7)4 (4.5)0.971
 Pulmonary surgery history9 (4.1)7 (5.4)2 (2.3)0.253
Clinical manifestations
 Cough217 (100)129 (100)88 (100)1.000
 Sputum production216 (99.5)129 (100)87 (98.9)1.000
 Shortness of breath166 (76.5)112 (86.82)54 (61.4)<0.001
 Exertional dyspnea194 (89.4)118 (91.5)76 (86.4)0.230
 Hemoptysis50 (23.0)36 (27.9)14 (15.9)0.039
 Body weight loss33 (15.2)25 (19.4)8 (9.1)0.038
 Crackle119 (54.8)72 (55.8)47 (53.4)0.727
 Wheezing53 (24.4)30 (23.3)23 (26.1)0.628
Laboratory findings
pH7.41 (7.39, 7.43)7.41 (7.39, 7.43)7.41(7.39, 7.43)0.674
 PaCO2 (mmHg)40.7 (37.2, 45.3)40.8 (37.1, 45.6)40.5 (38.0, 44.7)0.865
 PaO2 (mmHg)80.0±15.778.2±14.782.7±16.80.037
 WBC (10 × 9/L)7.6 ± 2.77.3 ± 2.67.9 ± 2.70.143
 Neutrophil (%)63.3 ± 11.764.3 ± 11.461.9 ± 11.90.134
 CRP (mg/L)4.8 (1.6, 12.4)4.6 (1.6, 15.0)5.5 (1.5, 11.7)0.687
 ESR (mm/h)20.2 (9.2, 36.7)19.6 (8.0, 35.4)20.4 (10.3, 37.4)0.522
 Positive CHA test49 (22.6)30 (23.3)19 (21.6)0.773
Pulmonary function tests
 FVC (% pred)74.8 ± 20.672.6 ± 20.978.0 ± 19.90.058
 FEV1 (% pred)60.7±15.458.9±14.163.3±16.80.040
 FEV1/FVC65.0 ± 8.164.1 ± 7.466.2 ± 8.90.070
 FEF75 (% pred)39.8 (32.6, 55.9)38.2 (34.1, 54.5)41.4 (29.3, 57.5)0.712
 RV (% pred)149.4 (123.3, 178.5)152.6 (125.8, 181.6145.6 (121.3, 171.00.213
Microorganisms
Pseudomonas aeruginosa77 (35.5)58 (45.0)19 (21.6)<0.001
Haemophilus influenzae34 (15.7)22 (17.1)12 (13.6)0.496
Nontuberculous mycobacterium8 (3.7)5 (3.9)3 (3.4)1.000
Streptococcus viridans3 (1.4)3 (2.3)0 (0)0.273
Candida albicans19 (8.8)8 (6.2)11 (12.5)0.107
Acinetobacter baumannii5 (2.3)5 (3.9)0 (0)0.082
Neisseria bacteria16 (7.4)6 (4.7)10 (11.4)0.063
Klebsiella pneumoniae2 (0.9)2 (1.6)0 (0)0.516
Enterobacter cloacae4 (1.8)2 (1.6)2 (2.3)1.000

Data are presented as mean ± standard deviation, median (interquartile range), or numbers (percentages). BMI: body mass index; CHA: cold hemagglutination; CI: confidence interval; CRP : C-reactive protein; DPB: diffuse panbronchiolitis; ESR: erythrocyte sedimentation rate; FEF: forced expiratory flow; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; OR: odds ration; PaCO2: arterial pressure of carbon dioxide; PaO2: arterial pressure of oxygen; pH: potential of hydrogen; RV: residual volume; WBC: white blood cell. Disease duration was defined as the time from the first DPB symptoms onset to the first visit to hospital. Comparison of DPB subjects with and without bronchiectasis. A positive CHA test was defined as a value greater than 1 : 64.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.